KRAS and lung carcinoma: In this study, the clinical characteristics of LUAD patients were analyzed, and it was found that KRAS gene mutations were more common in men, people over 65 years old, and people with a history of smoking, which was consistent with the results of previous studies.[21] Dual-drug chemotherapy with nonspecific cytotoxic drugs is still the main treatment modality for patients with KRAS-mutated advanced lung cancer.